Plus: how could the COVID-19 testing market boom improve public flu awareness?
Though Novavax and Seqirus are the first collaborative COVID-19 vaccine and influenza vaccine developers, respectively, to present positive findings of co-administration in volunteers, there is anticipation this may become a standard practice in the coming fall and winter seasons.
What exactly COVID-19 and flu vaccine co-administration may look like is not yet well-defined, but experts anticipate it could be a win-win practice.
In the next segment of an interview with Contagion, Dr. Raja Rajaram, Medical Affairs Lead of EMEA at Seqirus, discussed how the trend of flu vaccination as a “behavioral norm” may help improve global COVID-19 immunization efforts.
“Some of the population may be going forward for their flu vaccines, and that is an opportunity to find out if they’ve had their COVID-19 vaccines,” he explained. At the same time, COVID-19 vaccine appointments may be an ideal opportunity to initiate flu vaccination behaviors in patients as well.
Rajaram also discussed the rapidly-expanding respiratory virus assay market, and how the switch from defining flu by test results rather than diagnostic code may help public health awareness efforts.
“What I do hope for after COVID-19 is that (the testing market) expands to include flu and other respiratory viruses, because it will help the public understand what is the disease burden every winter,” he said.
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.